CBR-2092, a novel, multi-functional, hybrid antibiotic for the treatment of Gram-positive bacterial infections in the hospital setting, including both acute and chronic disease syndromes mediated by staphylococci. CBR 2092 has completed single and multiple ascending dose phase 1 studies in humans.

Research Program Assets, including secondary hybrid antibiotic programs focusing on additional hospital-based indications, including Clostridium difficile associated disease (CDAD). Additional novel chemistry programs are focused on the boxazomycin class of antibiotics with broad-spectrum potential, and the CBR 703 class of RNA polymerase inhibitors for Gram-negatives.

Discovery Program Assets, focusing on a cell-based screening approach – SEKO for Systematic Efflux Pump Knockout - wherein panels of efflux-defective strains of key target pathogens have been employed to discover novel antibacterial leads including CBR-4830, a novel class of inhibitors of the MreB cell division protein.

Small Molecule Library, consisting of over 25,000 compounds.